Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Salix Pharmaceuticals has said that Dr Falk Pharma has granted Salix a license to its family of budesonide products in the US, which includes patent-protected budesonide rectal foam and a budesonide gastro-resistant capsule.
Subscribe to our email newsletter
Salix is required to make an up-front payment and regulatory milestone payments to Dr Falk Pharma, with the majority contingent upon achievement of US regulatory approval. In addition, Salix will pay royalties on net sales.
The products are approved and marketed in Europe, in the UK and Germany. In the US the rectal foam and gastro-resistant capsule products have patent coverage until 2015 and 2016, respectively.
Dr Falk Pharma markets budesonide in the UK as Budenofalk 2mg rectal foam for the treatment of distal active ulcerative colitis and as Budenofalk 3mg Gastro-resistant capsules for the induction of remission of mild to moderate active Crohn’s disease.